NeuroSense Secures $5M Private Placement at 25% Premium, CEO Joins Investment | NRSN Stock News
Summary
The warrants have a term of five years from the date of issuance and an exercise price of per share.Proceeds from the private placement will be delivered to NeuroSense in two separate tranches. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSenses strategy is to develop combined therapies targeting multiple pathways associated with these diseases.For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the risk of a delay in submission by the Company of its regulatory dossier, that regulatory approvals for PrimeC will be delayed or not obtained in or elsewhere; that the market opportunity in will not be as currently estimated; unexpected R&D costs or operating expenses, insufficient capital to complete development of PrimeC, a delay in the reporting of additional results from PARADIGM clinical trial, the timing of expected regulatory and business milestones, risks associated with meeting with the FDA and Health Canada to determine the best path forward following the results from PARADIGM clinical trial, including a delay in any such meeting; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data; the development and commercial potential of any product candidates of Neurosense; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSenses filings with the Securities and Exchange Commission (SEC). Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.